PRKAA1 and neoplasm: The discussion extendsto the importance for tumor-selective AMPK targeting, limitationsof cancer models for AMPK modulator evaluation, and the selectionof combination therapies, all factors for consideration in futureAMPK modulator development for anticancer treatment.